Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 39.26 +0.45 (+1.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding AG Basel American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation September 20, 2023 EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety Buy List Alert: 3 Pharma Stocks with Positive Trial Updates September 13, 2023 These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. Via InvestorPlace 2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street September 12, 2023 Find out why analysts have such high expectations for these stocks. Via The Motley Fool Why Novartis Stock Spiked Today July 18, 2023 A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today. Via The Motley Fool AI Integration In Biotech & Pharma: Companies Positioned To Benefit September 11, 2023 The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030 September 08, 2023 EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope September 07, 2023 Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, Via Benzinga FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition September 06, 2023 From Genentech Via Business Wire Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer September 01, 2023 Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS)... Via Benzinga Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer September 01, 2023 From Genentech Via Business Wire Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time August 30, 2023 The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme Via Benzinga 3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List August 28, 2023 Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. Via InvestorPlace Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update August 23, 2023 Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... Via Benzinga How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% August 23, 2023 Roche provided an update from its study in lung cancer using an anti-TIGIT drug. Via Investor's Business Daily Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study August 23, 2023 Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t Via Benzinga Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer August 23, 2023 From Genentech Via Business Wire Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition? August 21, 2023 Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, Via Benzinga Exposures Product Safety Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs Via Benzinga Is Regeneron Pharmaceuticals Still a Top Growth Stock? August 21, 2023 The biotech's focus on innovation could be a boon for shareholders. Via The Motley Fool What's Going On With Sonnet BioTherapeutics Stock Today? August 16, 2023 Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 (IL12-FHAB) in combination with Roche... Via Benzinga Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales August 14, 2023 The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. Via Investor's Business Daily Is TTOO Stock Really Worth $5? Or Just 5 Cents? August 09, 2023 TTOO stock has been red hot in recent days, but the story of MULN stock should give speculative investors in T2 Biosystems caution. Via InvestorPlace Is AbbVie Still a Good Dividend Stock to Buy? August 08, 2023 Find out if AbbVie can overcome sinking sales of its top-selling product. Via The Motley Fool Why Is Aravive Stock Sinking Today? August 03, 2023 Aravive Inc (NASDAQ: ARAV) shares plunged after the company's Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary... Via Benzinga Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations July 28, 2023 Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. Via Benzinga Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List July 26, 2023 The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen Via Benzinga Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories July 24, 2023 Wall Street Journal Via Benzinga Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy July 24, 2023 Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to Via Benzinga New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss July 20, 2023 From Genentech Via Business Wire Q2 Earnings Scorecard And Analyst Reports July 18, 2023 We now have Q2 results from 38 S&P 500 members. Via Talk Markets < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
